Topical therapies for the treatment of localized plaque psoriasis in primary care: A cost-effectiveness analysis

British Journal of Dermatology

Volumn 168, Issue 5, 2013, Pages 1095-1105

  Sawyer, L ^a   Samarasekera, E J ^b   Wonderling, D ^b   Smith, C H ^c  

^a Showa University Koto Hospital   (United Kingdom)

^b ROYAL COLLEGE OF PHYSICIANS   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BETAMETHASONE VALERATE; CALCIPOTRIOL; CALCITRIOL; CLOBETASOL PROPIONATE; COAL TAR; CORTICOSTEROID; DITHRANOL; VITAMIN D;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; META ANALYSIS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROCEDURES; PSORIASIS VULGARIS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TOPICAL TREATMENT;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EXTREMITIES; HUMANS; META-ANALYSIS AS TOPIC; MODELS, THEORETICAL; PRIMARY HEALTH CARE; PSORIASIS; QUALITY-ADJUSTED LIFE YEARS; SCALP; TORSO; TREATMENT OUTCOME; VITAMIN D;

EID: 84876986723     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12261     Document Type: Article

References (39)

1. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM,. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146: 891-5.
2. NHS Information Centre for Health and Social Care. Prescription Cost Analysis England. 2011. Available at: www.ic.nhs.uk/pubs/prescostanalysis2011 (last accessed 20 November 2012).
3. National Institute for Health and Clinical Excellence. Psoriasis: The Assessment and Management of Psoriasis: NICE Clinical Guideline 153. London: National Institute for Health and Clinical Excellence, 2012.
4. National Institute for Health and Clinical Excellence. The Guidelines Manual. London: National Institute for Health and Clinical Excellence, 2009.
5. Smith DR, Bottomley JM, Auland M, et al,. Heterogeneity in the treatment of moderately severe scalp psoriasis in Scotland-results of a survey of Scottish health professionals. Curr Med Res Opin 2011; 27: 239-49.
6. Samarasekera EJ, Sawyer L, Wonderling D,. et al. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. Br J Dermatol 2013; 168: 954-67.
7. Camarasa JM, Ortonne JP, Dubertret L,. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J Dermatolog Treat 2003; 14: 8-13.
8. Christensen OB, Mørk N-J, Ashton R, et al,. Comparison of a treatment phase and a follow-up phase of short-contact dithranol and calcipotriol in outpatients with chronic plaque psoriasis. J Dermatolog Treat 1999; 10: 261-5.
9. Langley RG, Gupta A, Papp K, et al,. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. Dermatology 2011; 222: 148-56.
10. Affleck AG, Bottomley JM, Auland ME, et al,. Cost effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland. Curr Med Res Opin 2011; 27: 269-84.
11. Bottomley JM, Auland ME, Morais J, et al,. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland. Curr Med Res Opin 2007; 2: 1887-901.
12. Guenther L, van de Kerkhof PC, Snellman E, et al,. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002; 147: 316-23.
13. Kragballe K, Hoffmann V, Ortonne JP, et al,. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Br J Dermatol 2009; 161: 159-66.
14. Brazier J, Roberts J, Deverill M,. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21: 271-92.
15. Douglas WS, Poulin Y, Decroix J, et al,. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002; 82: 131-5.
16. Jemec GB, van de Kerkhof PC, Enevold A, Ganslandt C,. Significant one week efficacy of a calcipotriol plus betamethasone dipropionate scalp formulation. J Eur Acad Dermatol Venereol 2011; 25: 27-32.
17. Kaufmann R, Bibby A, Bissonnette R, et al,. A new calcipotriol/ betamethasone dipropionate formulation (DaivobetTM) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205: 389-93.
18. -1) in the treatment of scalp psoriasis. Br J Dermatol 1994; 131: 678-83.
19. Tyring SK, Mendoza N, Appell M, et al,. A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial. Int J Dermatol 2010; 49: 1328-33.
20. van de Kerkhof PC, Hoffmann V, Anstey A, et al,. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol 2009; 160: 170-6.
21. van de Kerkhof PC, van der Valk PG, Swinkels OQ, et al,. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. Br J Dermatol 2006; 155: 800-7.
22. Joint Formulary Committee. British National Formulary, 62nd edn. London: British Medical Association and The Royal Pharmaceutical Society of Great Britain, 2011.
23. Katz HI, Prawer SE, Medansky RS, et al,. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica 1991; 183: 269-74.
24. Kragballe K, Austad J, Barnes L, et al,. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology 2006; 213: 319-26.
25. Kragballe K, Austad J, Barnes L, et al,. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006; 154: 1155-60.
26. Luger TA, Cambazard F, Larsen FG, et al,. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 2008; 217: 321-8.
27. Poulin Y, Papp K, Bissonnette R, et al,. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis. J Dermatolog Treat 2010; 21: 185-92.
28. Fleming C, Ganslandt C, Guenther L, et al,. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol 2010; 20: 465-71.
29. -1 ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol. Dermatology 2000; 201: 139-45.
30. Jemec GB, Ganslandt C, Ortonne JP, et al,. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol 2008; 59: 455-63.
31. Dawe RS, Wainwright NJ, Cameron H, Ferguson J,. Narrow-band (TL-01) ultraviolet B phototherapy for chronic plaque psoriasis: three times or five times weekly treatment? Br J Dermatol 1998; 138: 833-9.
32. Hallaji Z, Barzegari M, Balighi K, et al,. A comparison of three times vs. five times weekly narrowband ultraviolet B phototherapy for the treatment of chronic plaque psoriasis. Photodermatol Photoimmunol Photomed 2010; 26: 10-15.
33. Cameron H, Dawe RS, Yule S, et al,. A randomized, observer-blinded trial of twice vs. three times weekly narrowband ultraviolet B phototherapy for chronic plaque psoriasis. Br J Dermatol 2002; 147: 973-8.
34. Langley RG, Paller AS, Hebert AA, et al,. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol 2011; 64: 64-70.
35. Schofield J, Grindlay D, Williams H,. Skin Conditions in the U.K.: A Health Needs Assessment. Nottingham: Centre of Evidence Based Dermatology, University of Nottingham, 2009.
36. Buckley C, Hoffmann V, Shapiro J, et al,. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology 2008; 217: 107-13.
37. Curtis L,. Unit Costs of Social Health Care. Canterbury: Personal Social Services Research Unit, University of Kent, 2010.
38. Department of Health. NHS Reference Costs 2009-2010. Available at: www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-123459 (last accessed 4 April 2012).
39. Richards HL, Fortune DG, Griffiths CE,. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 370-9.